





THE EXPRESSION LEVEL OF GLUT-1 RECEPTOR IN THE BRAIN OF NICOTINE - DEPENDENT RAT

Dr. Anggraini Barlian (SITH)
Dr. Kusnandar Anggadiredja (SF)





A. INTRODUCTION




- Nicotine is an addictive substance with devastating effect on health. Smoking habit can lead to nicotine addiction.
- High risk diseases :
 - Respiration, Cardiovascular, Cancer → ACTIVE/ PASSIVE smokers
- Difficult to withdraw: 70% smokers intended to quit smoking → only 3% succeeded
- Some medications have been studied to be used for the treatment of nicotine addiction, and the methods widely used currently are nicotine replacement therapies (Berretini, 2005).
- Previous research:
 - The role of arachidonic acid pathway in drug dependent: Diclofenac as COX inhibitor decrease reward in rat nicotine addiction (Sjah, 2007)
 - Low dosage of diclofenac (1 mg/kg bw and 3,2 mg/kg bw) decreased EP receptor (Faridah, 2010; Anggraeny et al, 2012)

Nicotine and neurotransmitters




Benowitz, 2008

Neuro-signaling in nicotine addiction



Nestler, 2001

Arachidonic acid pathway: drug addiction and inflammation pathway



Background

- ❖ GLUT-1 is one of glucose transporters that plays important role in brain glucose transport (Gerhart et al., 1989; Maher et al, 1994; Kumagai et al., 1994)
- ❖ Chronic use of addictive substance influences the rate of metabolism in the brain, especially glucose metabolism (Volkow et al., 1997)
- ❖ Drug dependence and withdrawal changed brain glucose metabolism (Volkow et al., 1991)




GLUT-1 has important role in drug addiction

Aim of the research


- To study the expression of GLUT-1 receptor in nicotine dependent rat brain
- To study the effect of diclofenac as *Non Steroidal Anti Inflammatory Drugs* (NSAID) in GLUT-1 receptor expression

Research methodology



Outline for CPP test


- Nicotine 0.5 mg/kg 1x/hari i.p
- Preference test (CPP)



- Diclofenac 3.2 mg/kg i.p
Sebelum induksi nikotin



- Nicotine 0.5 mg/kg 1x/hari i.p
- Preference test (CPP)




- Diclofenac 3,2 mg/kg i.p
Before nicotine induction

Research design




Rat habituation

Pre conditioning






CPP Results







Based on CPP test, nicotine induced dependency in rats, and diclofenac reduced nicotine dependency.


Expression level of GLUT-1 mRNA in Hipocampus




Expression level of GLUT-1 mRNA in Bulbus




Expression level of GLUT-1 mRNA




Expression level of GLUT-1 receptor in Hipocampus




Dependence




Relapse




Expression level GLUT-1 receptor in bulbus




Relapse




Dependence




Expression level of GLUT-1 receptor




Expression level of GLUT-1 receptor mRNA




Expression level of Protein Receptor GLUT-1



Post-transcriptional modification: nicotine dependent (D/R) GLUT-1 receptor increased, diclofenac (D/R) decreased GLUT-1 receptor



POSSIBLE MECHANISM OF NICOTINE-DEPENDENT AND GLUT-1 RECEPTOR EXPRESSION, AND DICLOFENAC IN AA PATHWAY AS ANTI-ADDICTION DRUG



POSSIBLE MECHANISM OF NICOTINE-DEPENDENT AND GLUT-1 RECEPTOR EXPRESSION, AND DICLOFENAC IN AA PATHWAY AS ANTI-ADDICTION DRUG

Conclusion

- ❖ Nicotine reduced GLUT-1 receptor in mRNA level
- ❖ Diclofenac (3,2 mg) treatment increased GLUT-1 receptor in mRNA level
- ❖ There is post-transcriptional modification → in nicotine dependent rat brain GLUT-1 receptor in protein level increased
- ❖ Diclofenac (3,2 mg) treatment decreased GLUT-1 receptor in protein level